Buprenorphine Prescribing Restrictions and Nurse Practitioners
This paper examines the Drug Addiction Treatment Act of 2000 (DATA) and its restriction limiting buprenorphine prescribing authority to licensed physicians, thereby excluding nurse practitioners. Drawing on four peer-reviewed journal articles, the paper argues that this restriction contributes to a significant treatment gap for opioid-addicted patients — a gap that widened from roughly one million untreated individuals in 2005 to over 1.1 million by 2008. The paper reviews physician reluctance to prescribe buprenorphine, the role of reimbursement barriers, comparisons with methadone access, and evidence that nurse practitioners achieve comparable patient health outcomes to physicians. It concludes that amending DATA to allow supervised nurse practitioner prescribing of buprenorphine would meaningfully expand access to opioid addiction treatment without compromising patient safety.
- Introduction: DATA restricts buprenorphine to physicians, leaving addicts untreated
- Literature Review: Physician non-prescribing, GSF framework, and access barriers
- The Case for Expanding Access: Prescription opiate abuse surpasses heroin; APRN parity argued
- Rising Addiction Rates and Policy Gaps: Addiction totals rose 50% from 2005 to 2008
- Comparing Outcomes and Broadening the Prescriber Base: Patient outcomes equal under NPs; broader prescribing recommended
- Verdict: No rational basis for excluding nurse practitioners from prescribing
- Conclusion: Scale treatment responses to addiction severity
✍️ How to write this paper — guide, tools & examples ▾
What makes this paper effective
- Uses concrete statistical comparisons — 1.2 million untreated in 2005 rising to 1.105 million in 2008 — to give the policy argument measurable weight rather than relying solely on assertion.
- Grounds its recommendations in a named policy evaluation framework (the Geelhoed-Schouwstra Framework), showing awareness of structured policy analysis rather than purely rhetorical advocacy.
- Draws an analogy between opioid addiction and chronic diseases such as diabetes and cardiovascular disease, effectively countering the stigma-based resistance to expanding prescribing access.
Key academic technique demonstrated
The paper demonstrates evidence-based policy analysis: it synthesizes findings from multiple peer-reviewed sources to build a cumulative case for legislative reform, using each article to address a different dimension of the problem — legal barriers, physician behavior, patient outcomes, and scope-of-practice equity — before arriving at a clearly stated authorial position in the "Verdict" section.
Structure breakdown
The paper opens with a problem statement situating the DATA restriction within the broader opioid crisis. A literature review section covers four scholarly articles in sequence, each adding a layer of evidence. A separate "Verdict" section explicitly distinguishes the author's own conclusions from the reviewed literature — a transparent move that separates summary from argument. The conclusion briefly restates the proportionality principle (scaling treatment to addiction severity) and calls for policy reconsideration.
Introduction
The Drug Addiction Treatment Act of 2000 certainly had noble intentions and meaningful safeguards. There is a definitive reason why physicians are allowed a certain set of rights and responsibilities, and why nurse practitioners occupy a somewhat different position in terms of prescribing rights. Anything related to opiates should be regulated stringently, as the opportunity to abuse prescribing privileges is real and difficult to ignore. However, equally difficult to ignore is the rampant abuse and addiction that has resulted, a problem aggravated by the fact that drugs containing buprenorphine are restricted to physicians only — despite the immeasurable benefit that prescribing such drugs could render to addicted persons. While restricting access to such drugs is not inherently unreasonable, in the case of buprenorphine the restriction is counterproductive given the number of addicted and untreated people. This paper uses scholarly and peer-reviewed research to make the case for why this policy needs to change.
References
Fornili, K., & Burda, C. (2009). Buprenorphine prescribing: Why physicians aren't and nurse prescribers can't. Journal of Addictions Nursing, 20(4), 218–226.
O'Connor, A. B. (2011). Nurse practitioners' inability to prescribe buprenorphine: Limitations of the Drug Addiction Treatment Act of 2000. Journal of the American Academy of Nurse Practitioners, 23(10), 542–545.
Rundio, A. (2012). Buprenorphine prescribing by APRNs. Journal of Addictions Nursing, 23(1), 80–81.
Strobbe, S., & Hobbins, D. (2012). The prescribing of buprenorphine by advanced practice addictions nurses. Journal of Addictions Nursing, 23(1), 82–83.
Already a member? Log in
Unlock the rest of this paper
135,000+ research papers · AI writing tools · Plagiarism & AI detection
24-Hour Pass
Does not renew
Get 24-Hour PassMonthly
Renews at $12.99/month until canceled
Start MonthlyAnnual
Renews at $99/year until canceled
Start Annual- Unlimited AI writing tools
- Plagiarism and AI text detection tool
Plan details
Unlimited AI writing tools are for individual, non-automated use and are subject to our Terms of Service and abuse-prevention measures.
TextChecker scans: 1 during the 24-Hour Pass, or 5 per month with Monthly and Annual.
Prices exclude applicable tax.
Always verify citation format against your institution’s current style guide requirements.